Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
Could Ginkgo Bioworks Holdings (NYSE: DNA) one day be part of the healthcare sector's version of the "Magnificent Seven" group of high-performing stocks? It's more likely than you think. The Boston-based biofoundry has large aspirations to disrupt the way new drugs are developed -- and there's reason to believe that over time it could succeed in a big way. Consider the following.
Perhaps the most illustrious of the current Magnificent Seven stocks (which all focus on technology) is Nvidia, the graphics-card and chipmaker business that's seeing its shares reach meteoric heights. It's risen 497% in three years as a result of the swelling hype about its role in the rollout of artificial intelligence (AI).
In essence, it sells shovels that its customers need to claim their own portion of the ongoing AI gold rush. The current expectation is that demand for those shovels will keep rising sharply, and that Nvidia will be consistently able to meet demand -- while also continuing to innovate so that its tools remain the most appealing option.
Source Fool.com
